Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart procedure offers hope for stubborn chest pain

NCT ID NCT06992830

Disease control Sponsor: Zhibing Lu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a minimally invasive procedure called cardioneuroablation for people with variant angina (chest pain from heart artery spasms) that doesn't improve with medication. The procedure uses a catheter to target nerve clusters on the heart to reduce abnormal signals that may trigger spasms. The study will enroll 16 adults aged 18-80 to see if the procedure safely reduces pain and spasm episodes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

16 people

The number who actually took part.

Started

Feb 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age between 18 and 80 years; * variant angina; * positive ergonovine provocation test; * refractory to antispasmodic drug therapy, or inability to achieve adequate symptom control due to drug intolerance, poor adherence, or unwillingness to take medications regularly. Exclusion Criteria: * cardiogenic shock; * chronic heart failure; * life expectancy less than 12 months; * current participation in another clinical study without completing the primary endpoint visit; inability to provide informed consent; * women of childbearing potential without effective contraception or who are breastfeeding; * coronary artery stenosis ≥50% or FFR ≤0.80; * sick sinus syndrome or high-degree AV block without pacemaker; * systolic blood pressure \<90mmHg or heart rate \<50 bpm; * allergy to diltiazem, nitrates, or nitroglycerin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Variant angina are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Prinzmetal angina

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Variant angina

Contacts and locations

Locations

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.